In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

Findings seen in combination with chemotherapy following surgery in patients with curative intent. HealthDay News — Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in ...

Adding pembrolizumab to modern, high-quality chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer.

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for ...

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.